Page last updated: 2024-12-11
cryptophycin 1
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6438401 |
| CHEMBL ID | 441018 |
| SCHEMBL ID | 1346966 |
| MeSH ID | M0234038 |
Synonyms (19)
| Synonym |
|---|
| 10-((3-chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone |
| cryptophycin 1 |
| 1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-((3-chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)- |
| CHEMBL441018 |
| cryptophycin a |
| (3s,6r,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone |
| C16877 |
| xo974v2m5t , |
| unii-xo974v2m5t |
| 124689-65-2 |
| cyclo((2r)-2-methyl-.beta.-alanyl-(2s)-2-hydroxy-4-methylpentanoyl-(2e,5s,6s)-5-hydroxy-6-((2r,3r)-3-phenyl-2-oxiranyl)-2-heptenoyl-3-chloro-o-methyl-d-tyrosyl) |
| cryptophycin-1 [mi] |
| .beta.-alanine, n-(3-chloro-n-(5-((2-hydroxy-4-methyl-1-oxopentyl)oxy)-1-oxo-6-(3-phenyloxiranyl)-2-heptenyl)-o-methyl-d-tyrosyl)-2-methyl-, .xi.-lactone, (2r-(2.alpha.(1(r*),2e,5s*(s*),6s*),3.beta.))- |
| cryptophycin-1 |
| cyclo((2r)-2-methyl-.beta.-alanyl-(2s)-2-hydroxy-4-methylpentanoyl-(2e,5s,6s)-5-hydroxy-6-((2r,3r)-3-phenyloxiranyl)-2-heptenoyl-3-chloro-o-methyl-d-tyrosyl) |
| SCHEMBL1346966 |
| PSNOPSMXOBPNNV-VVCTWANISA-N |
| Q27293933 |
| DTXSID901046187 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (16)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tubulin beta-4A chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin beta chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 2.0529 | 10.0000 | AID214507 |
| Tubulin alpha-3C chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin alpha-1B chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin alpha-4A chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin beta-4B chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin beta-3 chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.8945 | 10.0000 | AID214507 |
| Tubulin beta-2A chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin beta-8 chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin alpha-3E chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin alpha-1A chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin alpha-1C chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9555 | 10.0000 | AID214507 |
| Tubulin beta-6 chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin beta-2B chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9680 | 10.0000 | AID214507 |
| Tubulin beta-1 chain | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.0005 | 1.9870 | 10.0000 | AID214507 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | ED50 | 3.4000 | 0.4000 | 1.2825 | 3.4000 | AID214529 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (51)
Molecular Functions (21)
Ceullar Components (36)
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID403240 | Cytotoxicity against human SKOV3 cells | 1997 | Journal of natural products, Mar, Volume: 60, Issue:3 | Three new cryptophycins from Nostoc sp. GSV 224. |
| AID214529 | In vitro effective concentration required to reduce the amount of microtubules assembly by tubulin assay | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24. |
| AID403242 | Cytotoxicity against human KB cells | 1997 | Journal of natural products, Mar, Volume: 60, Issue:3 | Three new cryptophycins from Nostoc sp. GSV 224. |
| AID103090 | In vitro cytotoxicity against human MCF-7/Adr breast cancer cell line | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24. |
| AID403241 | Cytotoxicity against human LoVo cells | 1997 | Journal of natural products, Mar, Volume: 60, Issue:3 | Three new cryptophycins from Nostoc sp. GSV 224. |
| AID235113 | Resistance factor was expressed as the IC50 of resistance cell line / IC50 of sensitive cell line | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. |
| AID103723 | In vitro cytotoxicity against human MCF-7 cell line | 2004 | Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3 | Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24. |
| AID103750 | Inhibitory activity against MCF-7 cells after 72 hr cell growth | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24. |
| AID88942 | Antiproliferative activity was evaluated by the 72 hr MTT cell viability assay using human colon carcinoma cells (GC3). | 1999 | Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1 | Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region. |
| AID104087 | In vitro inhibitory activity of compound against induced cytotoxicity in MCF-7 cell line | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. |
| AID224783 | Compound was tested for its antitumor activity in murine pancreatic adenocarcinoma PO3 model at the maximum tolerated dose(MTD) | 1999 | Bioorganic & medicinal chemistry letters, Jan-04, Volume: 9, Issue:1 | Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region. |
| AID333122 | Cytotoxicity against human KB cells | 2004 | Journal of natural products, Aug, Volume: 67, Issue:8 | Isolation and structure determination of cryptophycins 38, 326, and 327 from the terrestrial cyanobacterium Nostoc sp. GSV 224. |
| AID126108 | Tested in vitro for the concentration that reduces the amount of pelleted protein by 50% in microtubule assembly assay. | 1998 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15 | Halohydrin analogues of cryptophycin 1: synthesis and biological activity. |
| AID103086 | In vitro inhibitory activity of compound against induced cytotoxicity in multidrug-resistant MCF-7/ADR breast cancer cell line | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. |
| AID103764 | Inhibitory activity against MCF7-ADR cells after 72 hr cell growth | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24. |
| AID226696 | In vitro inhibitory activity of compound against microtubule polymerization in a tubulin assembly assay | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. |
| AID80697 | Inhibitory activity against HCT116 cells after 24 hr cell growth | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24. |
| AID214507 | Concentration required to reduce the amount of pelleted tubulin | 2003 | Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4 | Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24. |
| AID38061 | Tested in vitro for the concentration that inhibits the proliferation of B16 melanoma cells by 50% after 72 hr of growth in cell proliferation assay | 1998 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15 | Halohydrin analogues of cryptophycin 1: synthesis and biological activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.69) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||